Background This study aimed to characterize the molecular basis of a -thalassaemia heterozygote who had a normal haemoglobin A 2 level.
Introduction
The thalassaemias are common genetic disorders characterized by reduced or absent synthesis of the globin chain. 1 In Thailand, 20^30% of the population are -thalassaemia carriers, and the prevalence of -thalassaemia carriers is 3^9%. 2 It is therefore possible that individuals may be compound heterozygotes for both -and -thalassaemias. Homozygous forms of -thalassaemia are usually expressed as chronic anaemia requiring regular blood transfusion. Heterozygous forms of -thalassaemia are normally associated with microcytic erythrocytes and reduced red cell haemoglobin, similar to those seen in -thalassaemia 1 traits. The percentage of haemoglobin A 2 is, however, elevated, which is the most characteristic feature that allows -thalassaemia carriers to be di¡erentiated from those ofthalassaemia. 3 We here describe a molecular characterization of a Thai individual heterozygous for o -thalassaemia who had an otherwise normal haemoglobin A 2 level.
Case report
The subject was a 21-year-old Thai woman who was selected from our ongoing programme of thalassaemia screening because routine laboratory analyses could not de¢ne an appropriate genotype. She was positive for a 0 ¢ 36% saline one-tube osmotic fragility test 4 but negative for a modi¢ed dichlorophenolindophenol (DCIP) dye precipitation test for haemoglobin E. 5 These are dual screening tests currently used for the prevention and control of thalassaemia in Thailand. In our laboratory the sensitivity and speci¢city of the 0¢36% saline osmotic fragility test for screening ofthalassaemia 1 and -thalassaemia are 100% and 80%, respectively. The DCIP precipitation test for haemoglobin E has a sensitivity of 99¢8% and a speci-¢city of 98¢3% (unpublished data). Her haematological data, determined using standard methods, were as follows: haemoglobin 124 g/L, haematocrit 38¢2%, mean corpuscular volume (MCV) 69¢3 fL, mean corpuscular haemoglobin (MCH) 22¢5 pg, mean corpuscular haemoglobin concentration (MCHC) 32¢4 g/dL and red cell distribution width (RDW) 15¢5%. Her serum ferritin was 75 g/ L, measured using a microparticle enzyme immunoassay. 6 Haemoglobin electrophoresis in alkaline cellulose acetate showed haemoglobins A and A 2 , of which haemoglobin A 2 accounted for 2¢0% as measured by DEAE cellulose microcolumn chromatography 7 and 2¢2% by a variant automated high performance liquid chromatography (HPLC) system (Bio-Rad Laboratories, Hercules CA, USA). In our laboratory, the range of haemoglobin A 2 in normal adults and -thalassaemia carriers is usually in the range of 2¢0^3¢5% and 4¢07 ¢0 %, respectively.
DNA analysis
DNA was extracted from peripheral blood leukocytes using standard methods. Screening for known -globin gene mutations causing thalassaemia in Thailand was performed using an allele-speci¢c polymerase chain reaction (PCR) and other PCR-related methods. 8^10 In each allele-speci¢c PCR tube, two additional primers were included with the sequences (5'-GGCCTAAAAC-CACAGAGAGT-3') and (5'-CCAGAAGCGAGTGTGTG-GAA-3'). These amplify a 578 bp speci¢c fragment from ¡ 564 to ‡ 14 of the G -globin gene and act as internal controls for the ampli¢cation reaction. Thethalassaemia 1 with the southeast Asian deletion was detected using the PCR as previously described. 11 For the detection of -thalassaemia 2 with the 3¢7 kb and 4¢2 kb deletions by PCR, three additional pairs of primers were designed and synthesized as shown in Fig The PCR cycling condition using the DNA Thermal Cycler 480 (Perkin-Elmer Co, Norwalk CT, USA) was as follows: (948C 3 min), one cycle followe d by 10 cycles (948C 30 s^608C 30 s^688C 2 min) and 10 cycles (948C 30 s^608C 30 s^688C 2 min plus an additional 20 s extension per cycle). Ampli¢ed DNA was analysed directly by electrophoresis on 1 ¢ 5% agarose gel, and in some experiments transferred by Southern blotting to a nylon membrane before being hybridized to a digoxigenin^dUTP-labelled 2 -Pst1/ -globin gene probe (Boehringer-Mannheim Co., Germany). The hybridized band was detected using a protocol supplied by the manufacturer. -Globin genotyping of the patient was also determined by a standard Southern hybridization of genomic DNA digested with Bam H I and Bgl II as previously described. 12 The -globin gene of the patient was analysed using PCR and direct DNA sequencing as described elsewhere. 13 Seven polymorphic restriction sites in the -globin gene cluster, including the Hinc II site 5' to the -globin gene, the Hind III sites in the G and A -globin genes, the Hinc II sites in the -globin gene and in its 3' region, the Ava II site in the -globin gene and the Bam H I site 3' to the -globin gene were determined using PCR followed by restriction digestion. 4 Figure 1 (a) demonstrates the PCR detection of -thalassaemia 2 used in this study. A normal individual and known cases of -thalassaemia 2 heterozygotes with 3¢7 kb and 4¢2 kb deletions were tested.Whereas the 1395 bp control fragment produced by primers ( G1 ‡ G11) was observed in all three cases, the 1779 bp and1529 bp fragments were speci¢cally found in the known -thalassaemia 2 heterozygotes with the 3¢7 kb and 4¢2 kb deletions, respectively ( Fig. 1b ). Southern hybridization with an -globin gene probe indicated that the ampli¢ed fragments were -globingene speci¢c (Fig. 1c) . Table 1 compares the haematologic parameters of the patient studied here with 34 pure -thalassaemia heterozygotes, 54 pure -thalassaemia 1 heterozygotes and two compound heterozygotes for -thalassaemia 1 and -thalassaemia encountered at our laboratory. Pure -thalassaemia heterozygotes had reduced MCV and MCH with elevated haemoglobin A 2 (6¢1 § 0¢4%). -Thalassaemia 1 heterozygotes had reduced MCV and MCH with normal haemoglobin A 2 levels (2¢4 § 0¢5%). Haemoglobin A 2 was, however, raised in both compound heterozygotes (5¢4% and 6¢1%, respectively). The patient studied in this report had a normal haemoglobin level with reduced MCV and MCH and a normal level of haemoglobin A 2 (2¢0%), compatible with a possible inheritance of -thalassaemia 1. DNA from the patient was therefore subjected to PCR analysis for the detection of -thalassaemia. No -thalassaemia 1 deletion was detected.With further investigation for the detection of -thalassaemia 2 shown in Fig. 1 , using primers A and B we detected a speci¢c PCR product diagnostic of the 3¢7 kb -thalassaemia 2 deletion. No normal fragment was obtained with primers G1 and G11. This result indicated a homozygosity for the 3¢7 kbthalassaemia 2 deletion in the patient. As shown in Fig. 2 , the ¢nding was also con¢rmed in a multiplex PCR manner for the simultaneous detection of -thalassaemia 2. Southern blot hybridization of Bam H I and Bgl II-digested genomic DNA of the patient with an -globin gene probe con¢rmed a homozygosity of the 3 ¢ 7 kb deletion in the patient (data not shown). Also shown in Fig. 2 is an allele-speci¢c PCR for the detection of common -thalassaemia variants in Thailand which unexpectedly demonstrated that the patient was also a carrier for o -thalassaemia with a 4 bp deletion (-CTTT) at codons 41 and 42 of the -globin gene. This is the most common -thalassaemia gene in Thailand. Dot blot analysis of the -globin gene with a speci¢c oligonucleotide probe 8 demonstrated the same result (not shown). Analysis of the ampli¢ed -globin gene of the patient revealed normal DNA sequences throughout the entire gene and its £anking regions. Analysis of the seven polymorphic sites in the -globin gene cluster described above revealed the pattern ( (3, 6 and 9) , known -thalassaemia 2 heterozygotes for the 4¢2 kb deletion (1, 4 and 7) and the 3¢7 kb deletion (2, 5 and 8) . M represents the -DNA/Hind III size markers. C: Hybridization of the gel in B with a digoxigenin-labelled -globin gene probe. 1-9 are as described in B.
Results
¡ , ‡ / ¡ , ‡ / ¡ ) for the patient, indicating that there was no gene deletion in the -globin gene cluster. It was therefore concluded that the patient represented an unusual case of a o -thalassaemia carrier with a low haemoglobin A 2 concentration, in combination with a homozygosity for the 3¢7 kb -thalassaemia 2 deletion.
Discussion
In Thailand, the purpose of the thalassaemia screening programme is to identify carriers with -thalassae-mia 1, -thalassaemia and haemoglobin E. 15 Under this programme, the carrier screening is carried out through double primary screening tests, namely a one-tube osmotic fragility test using 0¢36% bu¡ered saline 4 for the detection of -and -thalassaemia carriers and a modi¢ed dichlorophenolindophenol (DCIP) dye test 5 for detecting haemoglobin E. Samples identi¢ed as positive by either one or both of these two tests are then subjected to further haemoglobin analysis by electrophoresis or HPLC for the quanti¢cation of haemoglobins A 2 and E. An elevated level of haemoglobin A 2 is the main diagnostic feature of carriers 2 and 3 are the internal control ampli ed fragments from the G -globin gene promoter. Samples are 1, compound heterozygote for 41/42 and 17 ; 2, the patient; 3, normal control. The patient was found to be heterozygous for the -thalassaemia 41/42 mutation (lane 2) . B and C: the result of ampli cation using primers ( G1 ‡ G11) (B) and a multiplex single-tube PCR using primers (A ‡ B ‡ C ‡ D) for simultaneous detection of -thalassaemia 2 with 3¢7 and 4¢2 kb deletions (C). Samples are: 4 and 10, normal control; 5 and 11, -thalassaemia 2 carrier (3¢7 kb type); 6 and 12, -thalassaemia 2 carrier (4¢2 kb type); 7 and 13, -thalassaemia 2 homozygote (3¢7 kb/4¢2 kb); 8 and 14, the patient; 9 and 15, -thalassaemia 2 homozygote (4¢2 kb/4¢2 kb). The patient was homozygous for a 3¢7 kb -thalassaemia 2 deletion. M represents the -DNA/Hind III size markers. 
MCVˆmean corpuscular volume; MCHˆmean corpuscular haemoglobin; MCHCˆmean corpuscular haemoglobin concentration.
for -thalassaemia. 1 Those who have normal haemoglobin A 2 levels with low MCV and MCH values are considered to be at risk of being carriers for -thalassaemia 1, and these individuals require further PCR analysis for the detection of -thalassaemia 1. Individuals negative for the PCR test will be identi¢ed as non-thalassaemia carriers for the three types of thalassaemia mentioned above.
As shown in Table 1 , we have encountered a case who is a -thalassaemia carrier and who has a normal haemoglobin A 2 level (2¢0% measured by microcolumn chromatography and 2¢2% by automated HPLC). In our ongoing thalassaemia prevention and control programme, this individual was positive for a one-tube osmotic fragility test but negative for the DCIP dye test for haemoglobin E. No -thalassaemia 1 deletion was detected. However, the patient had low MCV and MCH values with normal Hb and Hct resembling that of a thalassaemia carrier. We therefore investigated this case further. Screening for thalassaemia mutations and the measurement of serum ferritin were therefore carried out. The serum ferritin concentration was found to be within the reference range (75 g/L). However, we have unexpectedly found that the patient was a carrier of a severe o -thalassaemia mutation resulting from a 4 bp deletion in codons 41 and 42. Further DNA analysis demonstrated that the patient was also homozygous for the -thalassaemia 2 3¢7 kb deletion. Both thethalassaemia codons 41 and 42 mutation and thethalassaemia 2 3¢7 kb deletion are common in Thailand. 8, 12 There are many reasons for reduced levels of haemoglobin A 2 in -thalassaemia heterozygotes. 3 Most of the cases reported were associated with -thalassaemia. 16^19 A borderline level of haemoglobin A 2 may indicate the presence of a silent or mild -thalassaemia gene. 17 It has been found that patients with severe iron de¢ciency anaemia also have reduced haemoglobin A 2 , 20 although it has since been shown that iron de¢ciency rarely if ever interferes with the diagnosis of -thalassaemia. 21 All these conditions could not explain the low level of haemoglobin A 2 in our case. As also described in previous reports, 22, 23 we have found that coinheritance of -thalassaemia 1 with -thalassaemia trait does not interfere with the diagnosis of -thalassaemia carriers as the haemoglobin A 2 level is still higher than normal (Table 1 ). An observation that homozygosity for the 3¢7 kb deletion of -thalassaemia 2 (either alone or in combination with other unknown factors) can cause a marked reduction in haemoglobin A 2 , such that an accurate diagnosis of -thalassaemia carrier is not possible without DNA analysis, is therefore interesting. Our ¢nding should have practical implications for population screening of thalassaemia 24 in regions where both -and -thalassaemias occur simultaneously. We conclude that individuals heterozygous for -thalassaemia 1may be distinguished from those with both -thalassaemia 1 and -thalassaemia by the former having a normal haemoglobin A 2 level. Screening for -thalassaemia in an -thalassaemia 1 carrier with normal haemoglobin A 2 is unnecessary. However, subjects positive for a one-tube osmotic fragility test who have normal levels of haemoglobin A 2 , reduced MCV and MCH, but who are negative for -thalassaemia 1 mutations, should be extensively studied in case they are heterozygous for -thalassaemia, especially when they marry a typical -thalassaemia or haemoglobin E carrier. The approach used to characterize the patient described in this report will prove useful for this investigation.
